Skip to main content

NovaBridge Biosciences

NBP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001778016

In the last 90 days, NovaBridge Biosciences insiders filed 0 open-market purchases and 3 sales; 49 institutions reported holding it in 13F filings for Q2 2026, worth $48.1M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.

Q3 2022 vs. Q2 2022

How the institutions holding NovaBridge Biosciences changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of NBP: Q2 2022 compared with Q3 2022
MeasureQ2 2022Of which not filed for Q3 2022Q3 2022Change
Holders97175−21
Shares38.2M1430.8M−7.45M (−19.5%)
Value$430.3M$158$123.3M−$307.0M (−71.3%)

1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (11)

Institutions that held NovaBridge Biosciences at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to NBP in Q3 2022
InstitutionSharesValue% of portfolio
Qube Research & Technologies Ltd166,548$668.0K0.00%
Renaissance Technologies LLC161,100$646.0K0.00%
Dimensional Fund Advisors LP48,437$194.0K0.00%
BNP Paribas Arbitrage, SA32,756$131.4K0.00%
Old Mission Capital LLC11,122$45.0K0.00%
ExodusPoint Capital Management, LP10,378$42.0K0.00%
Ronald Blue Trust, Inc.502$6.00K0.00%
Simplex Trading, LLC1,248$5.00K0.00%
China Universal Asset Management Co., Ltd.497$2.00K0.00%
Money Concepts Capital Corp69$00.00%
Cutler Group LP200$00.00%

Sold out (32)

Institutions that held NovaBridge Biosciences at the end of Q2 2022 and filed for Q3 2022 without it.

Not filed for Q3 2022 yet (1)

Institutions that held NovaBridge Biosciences at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NBP in Q2 2022 that haven't filed for Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Exane Derivatives14$158